Wasserheit C - Search Results

1

High-intensity chemotherapy with peripheral blood progenitor cell support.

Fennelly D, Vahdat L, Schneider J, Reich L, Hamilton N, Hakes T, Raptis G, Wasserheit C, Kritz A, Gulati S, et al. Fennelly D, et al. Among authors: wasserheit c. Semin Oncol. 1994 Apr;21(2 Suppl 2):21-5; quiz 26, 58. Semin Oncol. 1994. PMID: 7515513 Review.

2

Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.

Fennelly D, Wasserheit C, Schneider J, Hakes T, Reich L, Curtin J, Yao TJ, Markman M, Norton L, Crown J. Fennelly D, et al. Among authors: wasserheit c. Cancer Res. 1994 Dec 1;54(23):6137-42. Cancer Res. 1994. PMID: 7525055 Clinical Trial.

3

Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.

Schneider JG, Crown JP, Wasserheit C, Kritz A, Wong G, Reich L, Norton L, Moore MA. Schneider JG, et al. Among authors: wasserheit c. Bone Marrow Transplant. 1994 Dec;14(6):877-84. Bone Marrow Transplant. 1994. PMID: 7536069 Clinical Trial.

4

High-intensity chemotherapy with hematopoietic support in breast cancer.

Crown J, Vahdat L, Fennelly D, Francis P, Wasserheit C, Hudis C, Kritz A, Schneider J, Hamilton N, Gilewski T, et al. Crown J, et al. Among authors: wasserheit c. Ann N Y Acad Sci. 1993 Nov 30;698:378-88. doi: 10.1111/j.1749-6632.1993.tb17230.x. Ann N Y Acad Sci. 1993. PMID: 7506505 Review.

5

Purging in autologous and allogeneic bone marrow transplantation.

Gulati SC, Lemoli RM, Acaba L, Igarashi T, Wasserheit C, Fraig M. Gulati SC, et al. Among authors: wasserheit c. Curr Opin Oncol. 1992 Apr;4(2):264-71. doi: 10.1097/00001622-199204000-00005. Curr Opin Oncol. 1992. PMID: 1591301 Review.

6

Abnormal liver function in patients undergoing autologous bone marrow transplantation for hematological malignancies.

Wasserheit C, Acaba L, Gulati S. Wasserheit C, et al. Cancer Invest. 1995;13(4):347-54. doi: 10.3109/07357909509031914. Cancer Invest. 1995. PMID: 7627720 Clinical Trial.

7

Strategies for reduction of anthracycline cardiac toxicity.

Speyer J, Wasserheit C. Speyer J, et al. Among authors: wasserheit c. Semin Oncol. 1998 Oct;25(5):525-37. Semin Oncol. 1998. PMID: 9783592 Review.

8

A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.

Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D'Alassandro A, Fornier M, Troso-Sandoval T, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. Sugarman S, et al. Among authors: wasserheit c. Breast Cancer Res Treat. 2009 Jun;115(3):609-12. doi: 10.1007/s10549-008-0152-9. Epub 2008 Aug 27. Breast Cancer Res Treat. 2009. PMID: 18751888 Clinical Trial.

9

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J. Wasserheit C, et al. J Clin Oncol. 1996 Jul;14(7):1993-9. doi: 10.1200/JCO.1996.14.7.1993. J Clin Oncol. 1996. PMID: 8683229 Clinical Trial.

10

Taxanes in adjuvant and neoadjuvant therapies for breast cancer.

O'Leary J, Volm M, Wasserheit C, Muggia F. O'Leary J, et al. Among authors: wasserheit c. Oncology (Williston Park). 1998 Jan;12(1 Suppl 1):23-7. Oncology (Williston Park). 1998. PMID: 9516599 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters